In-house vs. outsourcing and the decisions behind it
57.5% of respondents are manufacturing their cell therapy programs in-house, while 42.5% are manufacturing cell therapies with a partner.
57% of respondents who chose to manufacture in-house say that it was because they valued having better supply chain control.
53% of respondents who chose to outsource manufacturing say they did so due to a lack of in-house capacity, while just under a third say that it was to seek external manufacturing expertise.
